| 引用本文：陈珉惺, 丛鹂萱, 何江江, 徐源, 杨燕, 邹璇, 刘新宇, 金春林.我国药品GPO发展现状及策略分析[J].中国卫生政策研究,2019,12(11):34-38 |
|
| 我国药品GPO发展现状及策略分析 |
| 投稿时间：2019-06-19 修订日期：2019-09-21 PDF全文浏览 HTML全文浏览 |
| 陈珉惺1, 丛鹂萱1, 何江江1, 徐源1, 杨燕1, 邹璇2, 刘新宇3, 金春林1 |
1. 上海市卫生和健康发展研究中心(上海市医学科学技术情报研究所) 上海 200031;
2. 深圳市疾病预防控制中心 广东深圳 518055;
3. 深圳市卫生健康委员会 广东深圳 518031 |
| 摘要:介绍上海、深圳及其他地区药品集团采购（GPO）的发展现状，并将深圳与上海GPO模式进行对比，分析GPO发展及拓展过程中面临与现有政策和政策引导中的困扰和挑战，提出明确GPO在新形势下发展的定位、制定GPO本土化发展的游戏规则、建立规范GPO发展的监管体系等相关政策建议。 |
| 关键词:药品采购 集团采购组织 |
|
| Current situation and strategy analysis of drug GPO development in China |
| CHEN Min-xing1, CONG Li-xuan1, HE Jiang-jiang1, XU Yuan1, YANG Yan1, ZOU Xuan2, LIU Xin-yu3, JIN Chun-lin1 |
1. Shanghai Health Development Research Center(Shanghai Medical Information Center), Shanghai 200031, China;
2. Shenzhen Center for Disease Control and Prevention, Shenzhen Guangdong 518055, China;
3. Shenzhen Municipal Health committee, Shenzhen Guangdong 518031, China |
| Abstract:This paper introduced the development status of drug procurement for GPOs in Shanghai, Shenzhen and other regions in China. After comparing Shenzhen's GPO model with that of Shanghai, challenges and difficulties in the development of GPO and policy guidance were analyzed. Finally, a policy advice was suggested in favor of defining the GPO development orientation in the new situation, formulating the game rules for the development of GPO localization and establishing a regulatory system for the GPO development. |
| Key words:Drug procurement Group purchasing organization (GPO) |
| 摘要点击次数: 2372 全文下载次数: 951 |
|
|
|
|
|
